CogniCurrent

COGNICURRENT

Feb 6 • 09:00 UTC • 🇨🇳 China • South China Morning Post

Fosun Pharma’s US$1.55 billion Eisai deal signals shift to long-term partnerships

Fosun Pharma has signed a US$1.55 billion licensing deal with Japan's Eisai for a cancer drug, indicating a trend towards long-term partnerships in the global pharmaceutical industry.

#fosun pharma #eisai #cancer drug #china #long-term partnerships
Read Original Back to Feed

📡 Similar Coverage